GENOMICS IN PRECISION ONCOLOGY XCHANGE
February 8, 2023
Welcome to hubXchange’s West Coast Genomics in Precision Oncology 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in genomics-led oncology precision medicine strategies.
Discussion topics will cover Cancer Genomics, Translational Bioinformatics, Data Quality & Access and Genomics Informed Clinical Decisions.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Venue Details – DoubleTree by Hilton San Francisco Airport Hotel, 835 Airport Boulevard, Burlingame CA 94010-9949
Opening Address & Keynote Presentation
Are all oncogenic drivers already known? How can we identify ‘novel’ targets with current genomics platforms?
Analyzing genomes and transcriptomes of cancers at single-cell resolution [TBC]
4:45 – 5:45pm
Liquid-biopsy and tissue-biopsy for personalized cancer genomics
- What are the major challenges in personalized cancer genomics in therapeutic target selection and efficacy monitoring in precision medicine?
- What technological advancements have helped us interrogate these challenges with biopsies from complimentary sources?
- How can we validate the finding from liquid biopsy to support clinical trial?
- What can we learn from liquid and tissue biopsy to make informed decision?
Director of Bioinformatics, Amplify-Bio
Sam joined Amplify-Bio recently as director of bioinformatics, bringing years of experience in cancer genomics in various biopharmaceutical companies. Previously at PACT Pharma, Sam built computational biology team, led the bioinformatics efforts in IND filing and clinical trial in developing personalized TCR-T cell therapy. Prior to PACT, Sam held various positions with increasing responsibilities at Amgen where he contributed to drug discovery and target identification across multiple therapeutic areas in immunoncology and metabolic disorders. Sam has extensive experience in leading multi-functional team to develop cloud based NGS pipeline to support neoantigen-TCR based drug development.